| http://www.w3.org/ns/prov#value | - The time, cost and risk of these trials are an impediment to speedy development of innovative therapies, and thus a critical, although challenging area for innovation,??? said George Vradenburg, convener of the CEOi. ???We look forward to working with the Foundation for NIH to take advantage of their experience in managing large-scale collaborations, such as the Accelerating Medicines Partnership
|
